July 2021 - PsychedelicNewsWire (PNW)

FridayJul 30, 2021 2:40 pm

Ketamine Treatment Study Conducted During Pandemic Highlights Antidepressant Properties

The coronavirus pandemic has affected many industries and economies around the world, in addition to affecting global physical health, with continuous disconnection and social isolation aggravating the mental health crisis further. It has also emphasized the need to find new ways to improve the treatment of mental health conditions, with one recent study reporting that ketamine held the potential to become an effective treatment for depression when administered during the pandemic. Ketamine is mainly used as an anesthetic but has also demonstrated that it can be used to treat depression. The study, which was reported in the “Psychiatry Research” journal,…

ThursdayJul 29, 2021 2:53 pm

Congresswoman Introduces Amendment to Remove Barriers Impeding Psychedelic Research

Rep. Alexandria Ocasio-Cortez recently introduced an amendment in Congress that would remove a federal research barrier on psychedelics and, in turn, promote studies on the therapeutic potential of psychedelics such as ibogaine, psilocybin and MDMA. The congresswoman’s measure would be opposing an amendment that was first enacted in the late 1990s, which prohibits federal funds from being used in any activity that promotes the legalization of substances or drugs classified under Schedule I of the Controlled Substances Act. The measure also includes a provision that directs the FDA to establish a regulatory pathway allowing CBD to also be dispensed as…

WednesdayJul 28, 2021 1:30 pm

Psilocybin Causes Sustained Neural Connection Growth, Study Finds

Researchers from Yale University have discovered that one dose of psilocybin administered to mice causes a quick and lasting increase in connections between neurons in the area of the brain involved in cognitive processes, known as the medial frontal cortex. Their discovery was reported in the “Neuron” journal. Prior research has found that psilocybin, which is the active compound found in psilocybin mushrooms, has long-lasting and profound effects on mood and personality, with some preliminary studies providing evidence that the compound could be used to alleviate symptoms of mental health conditions such as depression. However, the mechanisms underlying these effects…

WednesdayJul 28, 2021 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Files Patent, Adds New Dimension to Development Strategy

Digital therapeutics platform is proprietary to Cybin and the subject of the company’s 13th patent application Company focused on utilizing, leveraging cutting-edge technologies to support drug-development candidates Cybin is confident this added focus will better enable the evaluation of patient outcomes Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotechnology company, has taken another step forward in its strategic focus on progressing psychedelic therapeutics, with the filing of its 13th provisional patent application (https://ibn.fm/xTawm). In addition to the patent filing, the company has also advanced the build-out of its digital therapeutics strategy. “The digital therapeutics platform, which is proprietary to Cybin and the…

TuesdayJul 27, 2021 3:00 pm

New Zealand to Conduct LSD Micro-Dosing Trial Targeting Cancer Patients

Researchers in New Zealand plan to run an LSD micro-dosing trial with patients in the advanced stages of cancer in an attempt to see whether the drug will improve their quality of life. The trial will be led by University of Auckland’s director of the postgraduate diploma in health psychology, Dr. Lisa Reynolds. In an interview with a popular radio station, Reynolds stated that thus far, research had shown that psychedelic substances such as LSD possessed the potential to increase spirituality, decrease depression and anxiety, decrease the fear of death, and improve an individual’s quality of life. The objective of…

MondayJul 26, 2021 2:00 pm

Analysis Suggests No Link Between Psychedelics and the Onset of Mental Health Conditions

Researchers theorize that psychedelic substances differ from other recreational drugs because they do not lead to compulsive use or addiction and neither do they harm an individual’s brain. An analysis conducted by researchers from the Department of Neuroscience at the Norwegian University of Science and Technology proves this, having found that the use of peyote, psilocybin mushrooms or LSD does not increase an individual’s risk of developing mental health conditions. They also found no association between various mental health conditions and the use of psychedelic substances, but they did discover significant links between fewer metal health issues and the use…

FridayJul 23, 2021 2:00 pm

Study Finds That Ketamine, Psilocybin Improve Attention in Rodent Models

A new study has found that low doses of ketamine and psilocybin can boost attention and intensify motivation associated with food in low-performing rodents. Guy Higgins, lead author of the study and CEO of InterVivo Solutions, the company that carried out the study, stated that interest in the pharmacological effects of low doses of NMDA antagonists is what led the research team to study psilocybin and ketamine. Anecdotal reports on micro-dosing psychedelics indicate that the substances improve cognitive function and mood in humans. However, very few appropriately controlled trials have been conducted in this field. Higgins explained that the objective…

ThursdayJul 22, 2021 2:45 pm

Researchers Call for Re-evaluation of Specialized Nerve Treatments for Chronic Pain

A study conducted by researchers from the Lawson Health Research Institute evaluated the use of specialized treatments for chronic pain and their effect on opioid prescriptions and the use of health care. A recent report by the “Toronto Star” stated that since 2011, the Ontario Health Insurance Plan had been billed more than $400 million for nerve block procedures. Paravertebral blocks (PVBs) are types of procedures classified under nerve blocks. They involve injecting drugs around the nerves where those nerves exit the spine’s bones at different locations depending on the chronic pain a patient is experiencing. The efficacy of paravertebral…

ThursdayJul 22, 2021 9:00 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Set to Preview Milestones for Novel Psychedelic Therapies in Investor Day Event

Tryp Therapeutics is a drug developer whose mission is to find novel solutions to conditions with otherwise unmet needs The company has distinguished itself by developing a synthetic oral psilocybin product that it aims to use in the treatment of chronic pain and eating disorder indications under its psychedelic medicine research program Tryp’s management team will address investors in a Fiscal Q3 review on July 29 that also serves as an opportunity to talk about upcoming milestones for the company Venture capital investment interest in psychedelic therapies has grown explosively from $1 million in 2017 to $329 million during the…

WednesdayJul 21, 2021 3:00 pm

Can Psychedelics Be Used to Heal Moral Injuries?

Moral injury is the social, behavioral, psychological and spiritual distress that occurs in response to witnessing a behavior or acting in a way that doesn’t align with an individual’s moral beliefs and values. Researchers assert that moral injuries are not psychiatric diagnoses but may manifest as self-handicapping and avoidant behaviors, thoughts of systemic failures and personal regret, sadness, disgust, anger, shame and guilt. These injuries have been linked to considerable impairment in occupational, health and relational functioning and are considered to be less normative and more syndromal moral pain. PTSD and moral injuries often co-exist, but researchers note that while…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: July 2021